Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, early stage

5253 - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

Date

20 Oct 2018

Session

Poster Discussion session - Breast cancer, early stage

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Michael Untch

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

M. Untch1, C. Jackisch2, A. Schneeweiss3, S. Schmatloch4, B. Aktas5, C. Denkert6, C. Schem7, H. Wiebringhaus8, S. Kümmel9, K. Rhiem10, M. Warm11, P.A. Fasching12, M. Just13, C. Hanusch14, J. Hackmann15, J. Blohmer16, J. Furlanetto17, V. Nekljudova18, G. von Minckwitz17, S. Loibl17

Author affiliations

  • 1 Clinic For Gynecology, Gynecologic Oncology And Obstetrics, Helios Klinikum Berlin Buch, 13125 - Berlin/DE
  • 2 Geburtshilfe Und Gynäkologie, Klinikum Offenbach GmbH, 63069 - Offenbach/DE
  • 3 National Center For Tumor Diseases, University of Heidelberg, 69115 - Heidelberg/DE
  • 4 Brustzentrum, Elisabeth Krankenhaus, Kassel/DE
  • 5 Women’s Clinic, University Clinics, Leipzig/DE
  • 6 Institute Of Pathology, Charite Berlin Mitte, 10117 - Berlin/DE
  • 7 Mammazentrum Hamburg, Hospital Jerusalem, Hamburg/DE
  • 8 Geburtshilfe Und Gynäkologie, St. Barbara-Klinik, Hamm/DE
  • 9 Breast Unit, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 10 Center For Familial Breast And Ovarian Cancer, UNIVERSITY HOSPITAL COLOGNE, 50931 - Cologne/DE
  • 11 Breast Center, City Hospital Holweide, Cologne/DE
  • 12 Department Of Gynecology And Obstetrics, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 13 Gynäkologie, Onkologische Schwerpunktpraxis, Bielefeld/DE
  • 14 Frauenklinik, Rotkreuzklinikum, Munich/DE
  • 15 Breast Center, Marien Hospital, Witten/DE
  • 16 Gynäkologie, Klinik für Gynäkologie am Campus Charité Mitte, 10713 - Berlin/DE
  • 17 Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 18 Statistics, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
More

Resources

Abstract 5253

Background

The GeparSepto trial demonstrated a higher pathological complete response (pCR) rate after weekly nP compared to P followed by epirubicin (E) plus cyclophosphamide (C) as neoadjuvant treatment for early BC. We report an updated analysis of the key secondary endpoints.

Methods

Patients (pts) with histologically confirmed primary BC were randomized 1:1 to either weekly nP 150mg/m2 (nP150) for 12 weeks, after study amendment 125mg/m2 (nP125) or weekly P 80mg/m2 for 12 weeks followed by E 90mg/m2 plus C 600mg/m2 q3w for 4 cycles. Pts with HER2+ BC received concurrent trastuzumab (Herceprin®) 6mg/kg (loading (LD) dose 8mg/kg) and pertuzumab 420mg (LD 840mg) q3w. Primary objective was pCR (ypT0 ypN0). Key secondary objectives were disease-free survival (DFS), overall survival (OS), peripheral sensory neuropathy (PSN). DFS rates before and after nP dose reduction are reported.

Results

Between 7/2012 and 12/2013, a total of 1229 pts were randomized, 1206 started treatment (nP n = 606, P n = 600), 455 pts started therapy before and 751 after the amendment. After a median follow-up of 49.7 months (range 0.5-64.0) 248 DFS-events (nP n = 103, P n = 145) and 137 deaths (nP n = 63, P n = 74) were reported. Overall, pts with nP had a significantly longer DFS compared to P (HR 0.67 [95%CI 0.52-0.87], p = 0.002); OS did not differ between the two arms. The 3-year DFS rates were nP150 85.5% vs P 75.2% (HR 0.66 [95%CI 0.46-0.96], p = 0.026) for pts treated before and nP125 88.2% vs P 84.1% (HR 0.68 [95%CI 0.48-0.97], p = 0.032) for those after the amendment. Pts treated with nP150 compared to pts with nP125 had less predominant HER2+ BC and Ki67>20% (24.2% vs 38.1%; 60.4% vs 74.3%, respectively), while ER/PR-negativity was more frequent (36.3 vs 29.0%) (Furlanetto et al. Breast Cancer Res Treat. 2017). PSN resolutions in the two cohorts will be presented at the meeting.

Conclusions

The nP dose reduction did not compromise the DFS compared to P. The lower DFS rates with nP150 compared to nP125 can be explained by the different risk profile of the two cohorts.

Clinical trial identification

NCT01583426.

Legal entity responsible for the study

GBG Forschungs GmbH.

Funding

The trial was financially supported by Celgene and Roche.

Editorial Acknowledgement

Disclosure

C. Jackisch: Grants: Celgene, outside the submitted work. A. Schneeweiss: Personal fees: Roche, Grants and personal fees: Celgene; Personal fees outside the submitted work: Pfizer, AstraZeneca, B. Aktas: Personal fees and non-financial support: Roche, Celgene; Personal fees from Novartis, Pfizer, outside the submitted work. C. Denkert: Personal fees: Teva, Novartis, Pfizer, Roche, Amgen, MSD Oncology; Other: Sividon Diagnostics, outside the submitted work. S. Kümmel: Consulting or advisory role: Amgen, Celgene, Roche, Novartis, Astra Zeneca, MSD, Somatec. P.A. Fasching: Personal fees: Celgene, during the conduct of the study; Grants and personal fees: Novartis; Personal fees: Pfizer, Roche, Teva, outside the submitted work. C. Hanusch: Personal fees:Celgene, Pfizer, Roche, Lilly, Novartis, outside the submitted work. G. von Minckwitz: Research funding (institute): Pfizer, Sanofi, Amgen, Roche, Novartis, Celgene, Teva, AstraZeneca, Myriad Genetics, Abbvie, Vifor Pharma. S. Loibl: Grants (institution): AbbVie, Amgen, AstraZeneca, Celgene, Novartis, Pfizer, Roche, Teva, Vifor during the conduct of the study as well as outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.